(Last updated : 2024-12-23 10:48:02)
  Kuniaki Katsui
   Department   Kawasaki Medical School  Kawasaki Medical School, Department of Radiology, Division of Radiation Oncology,
   Position   Professor
■ BooK
1. 2013/11   Chapter 15. Brachytherapy for Oral Cancer, Oral Cancer: Symptoms, Management and Risk Factors 
2. 2011   Chapter 2. Radiotherapy for Oral Cancer, Oral Cancer: Causes, Diagnosis and Treatment 
■ Journal
1. 2024/12 Case of Radiation-Induced Angiosarcoma after Breast-Conserving Surgery with Hypofractionated Radiotherapy in a Japanese Patient. 
2. 2024/11 Long-term outcomes of high-dose-rate brachytherapy and external beam radiotherapy without hormone therapy for high-risk localized prostate cancer. 
3. 2024/05/15 Radiation-induced pleomorphic liposarcoma after hypofractionated radiotherapy following breast-conserving surgery: A case report and literature review. 
4. 2024/03/07 Impact of the neutrophil-to-lymphocyte ratio on patients with locally advanced non-small cell lung cancer who suffer radiation pneumonitis during the course of induction chemoradiotherapy followed by surgery. 
5. 2024/03 Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis. 
Display all(75)
■ Presentation
1. 2024/04/12 Long-Term Results of Salvage High-Dose-Rate Brachytherapy for Local Recurrence of Prostate Cancer after Definitive Radiotherapy. (Speech,General) 
2. 2023/04/20 未治療限局性前立腺癌を対象としたMRI-US 画像融合下限局高線量率組織内照射療法(MRI-US fusion-guided ultrafocal high-dose-rate brachytherapy) の初期経験(第2 報)
A prospective study of MRI-ultrasound fusion-guided ultrafocal high-dose-rate brachytherapy (HDR-BT) for primary localized prostate cancer (Poster notice,General) 
3. 2023/04/16 ホルモン療法を併用しない高リスク前立腺癌に対する外照射併用高線量率組織内照射の長期治療成績の検討 (Speech,General) 
4. 2022/04/16 A preliminary report of a prospective study of MRI-ultrasound fusion-guided ultrafocal high-dose rate brachytherapy for localized prostate cancer (Speech,General) 
5. 2021/09 Phase I clinical trial of OBP-301, a novel telomerase-specific oncolytic virus, in combination with radiotherapy in esophageal cancer patients (Poster notice,General) 
Display all(39)